6-1 Month Momentum % is the total return of the stock from 6-month ago to 1-month ago. As of today (2024-04-19), Ionis Pharmaceuticals's 6-1 Month Momentum % is -8.59%.
The industry rank for Ionis Pharmaceuticals's 6-1 Month Momentum % or its related term are showing as below:
IONS's 6-1 Month Momentum % is ranked worse than 58.79% of 1519
companies
in the Biotechnology industry
Industry Median: -1.21
vs IONS: -8.59
Competitive Comparison
For the Biotechnology subindustry, Ionis Pharmaceuticals's 6-1 Month Momentum %, along with its competitors' market caps and 6-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ionis Pharmaceuticals 6-1 Month Momentum % Distribution
For the Biotechnology industry and Healthcare sector, Ionis Pharmaceuticals's 6-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Ionis Pharmaceuticals's 6-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 6-1 Month Momentum % measures the total return to a stock over the past six months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Ionis Pharmaceuticals 6-1 Month Momentum % Related Terms
Thank you for viewing the detailed overview of Ionis Pharmaceuticals's 6-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.
Ionis Pharmaceuticals (Ionis Pharmaceuticals) Business Description
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
IONS has been successfully added to your